Lower nivolumab doses show efficacy in international data while FDA regimens persist amid $31B annual US cost estimates

Chuck Manski halted nivolumab after six months once imaging cleared and toxicity mounted, mirroring reduced-dose or extended-interval protocols already standard in Canada, Israel, and Sweden. Indian oncologists documented durable responses at 40 mg flat dosing versus the US 240-480 mg schedule. These patterns emerged from real-world registries rather than company-sponsored trials, exposing how post-approval optimization rarely occurs once revenue models lock in maximum utilization.

Pharma incentives align against dose reduction: Merck recorded $32 billion from pembrolizumab in one year while Bristol Myers Squibb earned $10 billion from nivolumab. A 2024 modeling study across 29 agents projected $31 billion in US savings if minimum effective doses replaced labeled amounts. The 340B program and pharmacy benefit managers further capture margins on higher volumes, leaving patients to absorb toxicity and copay burdens documented in KFF and Vanderbilt Medicare analyses.

Regulatory agencies have issued guidance encouraging post-marketing dose studies yet lack enforcement mechanisms. Next required step is prospective non-inferiority RCTs comparing labeled versus reduced schedules with overall survival endpoints, funded independently of manufacturers, to quantify both efficacy margins and toxicity reductions before guideline changes.